Nuvation Bio Cash Flow Statement
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
5.00+0.05 (+1.01%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nuvation Bio free cash flow
In fiscal 2025, Nuvation Bio generated -$173.4 million of operating cash flow and spent $8.0 million on capital expenditures. That left free cash flow of -$181.4 million, a free-cash-flow margin of -288.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Nuvation Bio cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -204.63M | -567.94M | -75.80M | -104.20M | -86.85M | -41.66M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 1.74M | 683.00K | 222.00K | 199.00K | 184.00K | 103.00K |
| Stock-Based Compensation | 35.89M | 32.27M | 19.51M | 16.29M | 9.27M | 2.20M |
| Change in Working Capital | 12.13M | -7.54M | 47.00K | -4.11M | 6.90M | 2.23M |
| Operating Cash Flow | -173.43M | -130.41M | -68.00M | -96.11M | -68.19M | -36.53M |
| Capital Expenditures | -8.00M | 0 | — | — | — | — |
| Investing Cash Flow | 99.52M | 122.70M | 8.92M | 63.46M | -454.67M | -70.32M |
| Debt Issued | — | — | — | — | — | 135.66M |
| Financing Cash Flow | 202.53M | 331.00K | 628.00K | 1.33M | 625.53M | 133.13M |
| Net Change in Cash | 128.36M | -6.93M | -58.45M | -31.32M | 102.67M | 26.29M |
| Free Cash Flow | -181.43M | -130.41M | -68.00M | -96.11M | -68.19M | -36.53M |
This table shows 6 annual periods of Nuvation Bio's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NUVB's reporting calendar. What is a cash flow statement?